EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Clinical trial NCT05498389 · UNKNOWN

Trial details

NCT number: NCT05498389
Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Lung Non-Small Cell Carcinoma Advanced Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 EGFR Mutation-Related Tumors

Start date: 2023-06-01
Primary completion: 2024-07-01
Enrollment: 115

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.